Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto
Lykos Therapeutics said it remains dedicated to continuing development of its midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD) after…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is a healthcare reporter for the Clinical Trials Arena. Coming from a journalistic background Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Based in Manchester, Abigail has previously worked in local news and has interests in research into the treatment and prevention of cancer, heart disease and dementia.
-
-
FDA drug application costs set to rise to $4.3m from October
The US Food and Drug Administration (FDA) has announced the cost to file a drug using clinical data will jump…
-
Standing ovation for Gilead as it boasts perfect efficacy in HIV PReP trial
Gilead received a standing ovation after announcing its full, perfect efficacy data from the Phase III PURPOSE 1 trial of…
-
UNAIDS boss calls on Gilead to provide ‘miracle’ drug to developing countries
The UNAIDS executive director has called upon Gilead Sciences to make its ‘miracle’ drug lenacapavir for human immunodeficiency virus (HIV)…
-
Seventh patient ‘cured’ of HIV among highlights at AIDS 2024
Researchers will present data from a ‘first-of-its-kind HIV cure’ stem cell transplant at the upcoming AIDS 2024 Conference. Experts will…
-
How will a Labour government support the UK clinical trials industry?
On 4 July 2024, the people of the UK took to the polls and made their voice heard, voting for…
-
Novo Nordisk’s ocedurenone Phase III flop costs company $816m
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
-
NHS boss praises managers and leaders as Tories seek to scrap £1bn funding
The chief executive of the National Health Service (NHS) England spoke about her desire to ‘bolster management and leadership’ after…
-
FDA AdCom to question efficacy and safety concerns with Eli Lilly’s Alzheimer’s drug
Questions about a change of primary endpoint, treatment cessation and mortality reporting will be asked by a US Food and…
-
OCT Europe: Unless everyone is benefiting, what is the point?
Patient-centricity has been a buzzword in the clinical trial industry for the past few years with all the big pharma…